These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 9254895

  • 1. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice.
    Jungwirth A, Galvan G, Pinski J, Halmos G, Szepeshazi K, Cai RZ, Groot K, Schally AV.
    Prostate; 1997 Aug 01; 32(3):164-72. PubMed ID: 9254895
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.
    Jungwirth A, Pinski J, Galvan G, Halmos G, Szepeshazi K, Cai RZ, Groot K, Vadillo-Buenfil M, Schally AV.
    Eur J Cancer; 1997 Jun 01; 33(7):1141-8. PubMed ID: 9376196
    [Abstract] [Full Text] [Related]

  • 3. Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Pinski J, Halmos G, Szepeshazi K, Schally AV.
    Cancer; 1993 Dec 01; 72(11):3263-70. PubMed ID: 8242552
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix.
    Chatzistamou I, Schally AV, Szepeshazi K, Groot K, Hebert F, Arencibia JM.
    Cancer Lett; 2001 Sep 28; 171(1):37-45. PubMed ID: 11485826
    [Abstract] [Full Text] [Related]

  • 5. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice.
    Yano T, Pinski J, Szepeshazi K, Halmos G, Radulovic S, Groot K, Schally AV.
    Cancer; 1994 Feb 15; 73(4):1229-38. PubMed ID: 8313327
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160.
    Milovanovic SR, Radulovic S, Groot K, Schally AV.
    Prostate; 1992 Feb 15; 20(4):269-80. PubMed ID: 1376910
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II.
    Jungwirth A, Schally AV, Halmos G, Groot K, Szepeshazi K, Pinski J, Armatis P.
    Cancer; 1998 Mar 01; 82(5):909-17. PubMed ID: 9486581
    [Abstract] [Full Text] [Related]

  • 8. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
    Stangelberger A, Schally AV, Varga JL, Hammann BD, Groot K, Halmos G, Cai RZ, Zarandi M.
    Prostate; 2005 Aug 01; 64(3):303-15. PubMed ID: 15754342
    [Abstract] [Full Text] [Related]

  • 9. Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways.
    Plonowski A, Schally AV, Varga JL, Rekasi Z, Hebert F, Halmos G, Groot K.
    Prostate; 2000 Jul 01; 44(2):172-80. PubMed ID: 10881027
    [Abstract] [Full Text] [Related]

  • 10. Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice.
    Pinski J, Schally AV, Halmos G, Szepeshazi K.
    Int J Cancer; 1993 Dec 02; 55(6):963-7. PubMed ID: 7902829
    [Abstract] [Full Text] [Related]

  • 11. Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.
    Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K, O'Byrne K, Cai RZ.
    Br J Cancer; 1994 Nov 02; 70(5):886-92. PubMed ID: 7947094
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of growth of OV-1063 human epithelial ovarian cancers and c- jun and c- fos oncogene expression by bombesin antagonists.
    Chatzistamou I, Schally AV, Sun B, Armatis P, Szepeshazi K.
    Br J Cancer; 2000 Oct 02; 83(7):906-13. PubMed ID: 10970693
    [Abstract] [Full Text] [Related]

  • 13. Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095.
    Halmos G, Schally AV.
    Proc Natl Acad Sci U S A; 1997 Feb 04; 94(3):956-60. PubMed ID: 9023364
    [Abstract] [Full Text] [Related]

  • 14. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
    Pinski J, Reile H, Halmos G, Groot K, Schally AV.
    Cancer Res; 1994 Jan 01; 54(1):169-74. PubMed ID: 7903203
    [Abstract] [Full Text] [Related]

  • 15. Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma.
    Koppán M, Halmos G, Arencibia JM, Lamharzi N, Schally AV.
    Cancer; 1998 Oct 01; 83(7):1335-43. PubMed ID: 9762934
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II.
    Kahán Z, Sun B, Schally AV, Arencibia JM, Cai RZ, Groot K, Halmos G.
    Cancer; 2000 Mar 15; 88(6):1384-92. PubMed ID: 10717621
    [Abstract] [Full Text] [Related]

  • 17. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice.
    Stangelberger A, Schally AV, Varga JL, Zarandi M, Szepeshazi K, Armatis P, Halmos G.
    Clin Cancer Res; 2005 Jan 01; 11(1):49-57. PubMed ID: 15671527
    [Abstract] [Full Text] [Related]

  • 18. Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors.
    Lamharzi N, Schally AV, Koppán M.
    Regul Pept; 1998 Oct 16; 77(1-3):185-92. PubMed ID: 9809814
    [Abstract] [Full Text] [Related]

  • 19. Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist cetrorelix in DU-145 prostate tumor xenografts in nude mice.
    Lamharzi N, Halmos G, Jungwirth A, Schally AV.
    Int J Oncol; 1998 Sep 16; 13(3):429-35. PubMed ID: 9683774
    [Abstract] [Full Text] [Related]

  • 20. Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice.
    Shirahige Y, Cai RZ, Szepeshazi K, Halmos G, Pinski J, Groot K, Schally AV.
    Biomed Pharmacother; 1994 Sep 16; 48(10):465-72. PubMed ID: 7858155
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.